During Friday’s afternoon trade, Shares of VirtualScopics Inc (NASDAQ:VSCP), gained 153.33% to $4.56. The firm opened its current trade at $4.56. The total volume traded for the day is 11.35M shares, as compared to its average daily volume of 9,244.00 shares. The stock is floating in a range of $2.44 $6.65. The stocks hold the market capitalization of $9.69M.
Short-Term Price Target Update: The mean estimate for the short-term price target for the firm stands at $8.75, according to 1 brokers. The higher price target for VSCP is $8.75, while the lower price target is $8.75. In the past 52-weeks, the company shares have gained 12.47% and marked new high $6.65 on Mar 10, 2015. According to news report, VirtualScopics, Inc. (VSCP), stated financial results for the third quarter and nine months ended September 30, 2015. Revenues for the third quarter of 2015 raised 18% to $3,224,407 contrast to $2,741,241 for the third quarter of 2014. The company stated positive Adjusted EBITDA in the third quarter of 2015 of $132,101 as contrast to negative Adjusted EBITDA of $842,772 in the third quarter of 2014. VirtualScopics stated a net loss for the third quarter of 2015 of $24,779, or $0.02 loss per share, representing a 97% improvement from a net loss of $955,523, or $0.33 loss per share, stated in the third quarter of 2014. Revenues for the first nine months of 2015 were $9,057,975, a 17% improvement over the $7,742,974 stated for the preceding year period. The company stated a net loss for the first nine months of 2015 of $1,124,443, or $0.42 loss per share, representing a 52% improvement from the net loss of $2,333,427, or $0.82 loss per share, for the same period in 2014.
In addition, Converse continued, the backlog has grown to $31.9 million and we believe it will continue to grow. Our decision to focus on our core competencies has proven to be the right decision as we continue to strengthen our relationships with large pharma and develop new relationships with biotechs. This year we were chosen to be the sole imaging provider for several of our customers and most recently we were awarded a phase III oncology trial from yet another large pharma company.
VirtualScopics, Inc. provides imaging solutions to the pharmaceutical, biotechnology, and medical device industries. The company offers a suite of image analysis software tools and applications, which are used in detecting and measuring specific anatomical structures and metabolic activity using medical images.
This article is published by www.stocksnewswire.com. The content included in this article is just for informational purposes only. Stocksnewswire.com takes sensible consideration to ensure that the data given in this article is up to date and accurate. The news, prices, opinions, research, analysis, and other information published in this article are obtained from sources believed to be reliable.
Neither Stocksnewswire.com nor any of Stocksnewswire.com partners make any representation or guarantee as to the fulfillment or precision of the information contained in this article.
Investors must consult their own additional due diligence with any potential investment or highlighted company before making any decision on behalf of information offered by Stocksnewswire.com.
Information contained in this article may contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long-term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.